Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia

Next Previous
Trial Profile

A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitapivat (Primary)
  • Indications Alpha-thalassaemia; Beta-thalassaemia; Thalassaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Agios Pharmaceuticals

    • Most Recent Events

    • 13 Dec 2022 Results assessing the effect of mitapivat on markers of erythropoietic activity through Week 72, along with Hb and markers of hemolysis and iron homeostasis, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 10 Dec 2022 According to an Agios Pharmaceuticals media release, the company will host a live investor event o review the key clinical oral and poster presentations from this year ASH meeting.
    • 10 Dec 2022 According to an Agios Pharmaceuticals media release, data from the study were presented in a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top